CD8A and cancer: More specifically, studies have shown that cancer-derived EVs have the ability to interrupt the recruitment, activation and functionality of a number of key immune cells, including macrophages, regulatory T cells (Tregs), MDSCs, dendritic cells and cytotoxic CD8+ T cells [2,16,17].